Peapod Lane Capital LLC Buys 122,684 Shares of 4D Molecular Therapeutics, Inc. $FDMT

Peapod Lane Capital LLC boosted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 62.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 318,537 shares of the company’s stock after buying an additional 122,684 shares during the quarter. Peapod Lane Capital LLC owned approximately 0.69% of 4D Molecular Therapeutics worth $1,182,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in FDMT. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. Y Intercept Hong Kong Ltd purchased a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $41,000. AQR Capital Management LLC purchased a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $46,000. Russell Investments Group Ltd. purchased a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $63,000. Finally, Proficio Capital Partners LLC increased its position in 4D Molecular Therapeutics by 26.0% during the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock valued at $75,000 after purchasing an additional 5,195 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Roth Capital reduced their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Royal Bank Of Canada reiterated an “outperform” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.50.

4D Molecular Therapeutics Stock Up 13.4%

NASDAQ FDMT opened at $11.34 on Friday. The firm has a market cap of $529.58 million, a PE ratio of -3.21 and a beta of 2.93. The company has a 50 day moving average price of $8.00 and a 200 day moving average price of $5.41. 4D Molecular Therapeutics, Inc. has a 52 week low of $2.23 and a 52 week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. On average, equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.